外周 CD8⁺ T 细胞克隆性和 NK 细胞扩增标志惰性 B 细胞淋巴瘤对 mosunetuzumab 的早期应答

Peripheral CD8⁺ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma.

Shiheleucel（一种在化学成分明确条件下扩增的同种异体 NK 细胞产品）联合以利妥昔单抗为基础的化疗治疗复发/难治性弥漫大 B 细胞淋巴瘤：一项探索性临床研究

Shiheleucel, an allogeneic natural killer cell product expanded under chemically defined conditions, in combination with rituximab-based chemotherapy

利妥昔单抗结合赋予 B 细胞淋巴瘤中 CD20⁺ 细胞外囊泡 NK 细胞激活特性

Rituximab Binding Endows CD20+ Extracellular Vesicles With NK Cell-Activating Properties in B Cell Lymphoma.

弥漫大 B 细胞淋巴瘤的免疫治疗：从单克隆抗体到细胞治疗（叙述性综述）

Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review.

高亲和力 CD16(v/v) 异体 NK 细胞疗法 AB-101 增强 B 细胞驱动疾病中抗体介导的细胞毒性

High affinity CD16(v/v) allogeneic NK cell therapy, AB-101, enhances antibody-mediated cytotoxicity in B-cell driven diseases.

骨髓自然杀伤（NK）细胞对弥漫大 B 细胞淋巴瘤复发的预测价值：整合基于抗体依赖性细胞介导的细胞毒性（ADCC）的免疫治疗

Predictive value of natural killer (NK) cells in bone marrow for relapse in diffuse large B cell lymphoma: integrating antibody-dependent cell-mediate

NK 细胞百分比较高的患者可能更好地耐受化疗引起的耗竭，从而更有效地保存或恢复其效应细胞库。

既往 B 细胞清除后阿替利珠单抗与贝伐珠单抗治疗肝细胞癌获完全缓解

Complete Remission of Hepatocellular Carcinoma With Atezolizumab and Bevacizumab Following Prior B-cell Depletion.

慢性淋巴细胞白血病中的感染：不断演变的风险与预防策略

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies.

CD40L 与 IL-4 通过 HLA-E:NKG2A 轴抑制 NK 细胞介导的抗体依赖性细胞毒性

CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis.

这些结果揭示了 B 细胞恶性肿瘤中抗 CD20 治疗耐药的新机制，并表明抗 NKG2A 联合抗 CD20 可改善 CLL 或 NHL 患者的治疗。

现货型诱导多能干细胞来源的 NK 细胞疗法治疗复发/难治性 B 细胞淋巴瘤：一项多中心、开放标签、1 期研究

Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label,